Company intelligence / Profile preview

Jiangsu Biopharmaceutical

Jiangsu Sheng / Province, Chinaen.jsxtsw.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Jiangsu Jiye Biopharmaceutical focuses on macromolecular biotherapeutics, especially monoclonal antibodies for immune-related diseases, oncology, and respiratory conditions. Its lead asset JYB‑1904 targets IgE for chronic urticaria and is in Phase 2 trials. Other programs are at IND or early clinical stages targeting septic shock, advanced solid tumors, and kidney disease. The company serves as the macromolecular biologics production base for Jemincare Group.

Therapeutic areas: OncologyDermatologyNephrologyInfectious Diseases
Modalities: Monoclonal antibodyBiological products
Industry: Biotech

Beyond the preview

Go deeper on Jiangsu Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Biopharmaceutical.

Explore the full profile